Navigation Links
HealthCore presents ISPOR poster sessions
Date:5/20/2011

The verbal presentations are scheduled as follows:

SESSION I / Monday, May 23 / 8 a.m. - 8:30 p.m.

PCV106
Re-Hospitalization Rates of Acute Coronary Syndrome Patients in Real World Clinical Practice: Observations from a National Administrative Claims Data
Tunceli O1, Gandhi SK2, Bhandary D2, Stephenson JJ1, Gold A2, Fu AC1, Kern DM1, Singer J1 1HealthCore, Inc., Wilmington, Del.; 2AstraZeneca Pharmaceuticals LP, Wilmington, Del.

SESSION II / Tuesday, May 24 / 8 a.m. - 7:45 p.m.

PIN6
Trends of Hepatitis A Incidence from 2005 to 2008
Eisenberg D1, Changolkar AK2, Misurski DA2 1HealthCore, Inc., Wilmington, Del.; 2GlaxoSmithKline, Philadelphia, Pa.

PRS42
Concomitant Asthma Medication Use in Patients Using Omalizumab: Results from Three Large Insurance Claims Databases
Lafeuille MH1, Duh MS2, Zhang J3, Wertz D4, Gu T4, Tang J2, Lefebvre P1
1Groupe d'analyse, Lte, Montreal, Canada; 2Analysis Group, Inc., Boston, Mass; 3Novartis Pharmaceuticals Corporation, East Hanover, N.J/; 4HealthCore, Inc., Wilmington, Del.

SESSION III / Wednesday, May 25 / 8 a.m. 3 p.m.

PCN100
Racial Disparities in African-American Versus White Women with Newly Diagnosed Breast Cancer in a Southeast United States Health Plan
Fisher M1, Cai Q1, Paoli CJ2, Lyons A3, Wasser T1, Rodriguez N4, White S5, Kallich J3, Barron J1, Brawley OW6
1HealthCore, Inc., Wilmington, Del.,; 2University of California, San Francisco, San Francisco, Calif.; 3Amgen, Inc., Thousand Oaks, Calif.; 4Blue Cross Blue Shield of Georgia, Atlanta, Ga., 5WellPoint, Atlanta, Ga; 6American Cancer Society, Atlanta, Ga.

PGI2
Predictors of Proton Pump Inhibitor (PPI) Dosing Regimen Among Patients with Gastroesophageal Reflux Disease (GERD)
Eisenberg D1, Mody R2, Singer J1, Kamat SA1, Gerson LB3
1HealthCore, Inc., Wilmington, Del; 2Takeda Pharmaceuticals International, Inc., Deerfield, Ill.; 3Stanford University, Palo Alto, Calif.

PMH30
Indirect Costs (IC) of Adult Women with Anxiety Disorders (AD) in the United States in 2006 from the Medical Expenditures Panel Survey (MEPS)
Kavati A1, Rappaport H2
1HealthCore, Inc., Wilmington, Del; 2University of Louisiana at Monroe, Monroe, La.

PMH71
Health Care Resource Utilization (HCRU) and Direct Medical Expenditures (DME) for Adult Women with Anxiety Disorders (AD) in the United States in 2006 from the Medical Expenditures Panel Survey (MEPS)
Kavati A1, Rappaport H2
1HealthCore, Inc., Wilmington, Del.; 2University of Louisiana at Monroe, Monroe, La.

PMH78
Persistence of Stimulant Treatment in Children and Adolescents with Attention-Deficit Hyperactivity Disorder
Palli SR1, Aparasu RR2, Chen H2, Sherer JT2
1HealthCore, Inc., Wilmington, Del; 2University of Houston, Houston, Texas.

PMH79
Psychotropic Polypharmacy in Children and Adolescents with Attention Deficit / Hyperactivity Disorder
Palli SR1, Aparasu RR2, Chen H2, Sherer JT2
1HealthCore, Inc., Wilmington, Del; 2University of Houston, Houston, Texas.

PND36
Internal Locus of Control and Treatment Satisfaction with Natalizumab
Stephenson JJ1, KernDM1, Agarwal SS2, Kamat SA1
1HealthCore, Inc., Wilmington, Del.; 2Biogen Idec Inc., Weston, Mass.

PND39
Multiple Sclerosis Patients Report Improvements in Fatigue and Cognitive Functioning After One Year of Natalizumab Treatment
Stephenson JJ1, Kern DM1, Agarwal SS2, Kamat SA1
1HealthCore, Inc., Wilmington, Del.; 2Biogen Idec Inc., Weston, Mass.

PND45
One Year of Natalizumab Treatment is Associated with an Improvement in Health-related Quality of Life in Multiple Sclerosis Patients
Stephenson JJ1, Kern DM1, Agarwal SS2, Kamat SA1
1HealthCore, Inc., Wilmington, Del.; 2Biogen Idec Inc., Weston, Mass.


'/>"/>

Contact: Lori McLaughlin
lori.mclaughlin2@wellpoint.com
317-407-7403
HealthCore
Source:Eurekalert

Related medicine news :

1. AGA presents cutting-edge research during DDW
2. PI presents safety results in Neuralstem ALS Stem Cell Trial
3. Alfred B. Knight, M.D., Scott & White Healthcare, presents at 8th Annual World Health Care Congress
4. Cancer surgery society presents top honor to Kimberly Duchossois
5. Euthymics presents phase II data for EB-1010 in major depression at ACNP annual meeting
6. John Theurer Cancer Center presents studies on promising therapies for aggressive blood cancers
7. Professor Zvi Ram presents phase III recurrent glioblastoma survival and quality of life data from the first pivotal study of the NovoTTF-100A at 15th Annual Society for Neuro-Oncology Scientific Meeting
8. AAPS presents awards to exemplary researchers
9. Governor presents UH researcher with grant for cardiac device
10. Onconova Therapeutics presents new data demonstrating radioprotection by Ex-RAD at RRS annual meeting
11. APA presents latest research on same-sex marriage at annual convention in San Diego
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2016)... York, NY (PRWEB) , ... April 29, 2016 , ... New York City based oral ... . This surgery is a very effective way to treat obstructive sleep apnea. Dr. Jamali ... , Orthognathic surgery is a procedure that involves one or both jaw bones. This surgery ...
(Date:4/29/2016)... ... April 29, 2016 , ... Jvion, the market ... funding led by Eastside Partners, with participation from existing investor Martin Ventures. ... and accelerate its technology and product roadmap. , “Jvion is experiencing ...
(Date:4/29/2016)... , ... April 29, 2016 , ... ... print media enterprise focused entirely on patients with cancer, today announced that Lynne ... chosen as the 2016 CURE® Extraordinary Healer® for Oncology Nursing , which ...
(Date:4/29/2016)... ... April 29, 2016 , ... Natren, ... animal line of probiotics, Petbiotics ™, as they fondly call them. As ... rescue groups networking for their non-profit organizations. Animal rescues across the nation face ...
(Date:4/29/2016)... , ... April 29, 2016 , ... ... awareness for Duchenne muscular dystrophy, and funding for Duchenne research, participated in the ... of the Sarepta Therapeutic’s novel Duchenne drug eteplirsen. The meeting at the Marriott ...
Breaking Medicine News(10 mins):
(Date:4/29/2016)... -- Glycotope GmbH, a clinical-stage immuno-oncology company ... of Dr. Alfredo Zurlo as Chief Medical ... many years clinical experience and a proven track record ... was at Mologen AG where he was Chief Medical ... Zurlo held various positions at F Hoffmann La Roche ...
(Date:4/28/2016)...  Marking its one year anniversary since launching ... risk test, Color Genomics announced a ... impact the most common hereditary cancers affecting both ... analyzes hereditary cancer risks for breast, colorectal, melanoma, ... Color Test is physician ordered and includes genetic ...
(Date:4/28/2016)... 28, 2016 Dr. Vivek Ahuja ... and Ste phen Schmidt ... leading provider of cloud-based software solutions for life sciences, today announced ... bring a wealth of insight to a growing business.  This will ... George Phillips joined ArisGlobal in the position of ...
Breaking Medicine Technology: